The heidelberg bleeding classification: Classification of bleeding events after ischemic stroke and reperfusion therapy

Stroke

Volumn 46, Issue 10, 2015, Pages 2981-2986

  Von Kummer, Rüdiger ^a   Broderick, Joseph P ^b   Campbell, Bruce C V ^c   Demchuk, Andrew ^d   Goyal, Mayank ^d   Hill, Michael D ^d   Treurniet, Kilian M ^e   Majoie, Charles B L M ^e   Marquering, Henk A ^e   Mazya, Michael V ^f   Román, Luis San ^g   Saver, Jeffrey L ^h   Strbian, Daniel ⁱ   Whiteley, William ^j   Hacke, Werner ^k  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF CALGARY   (Canada)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g HOSPITAL CLÍNIC   (Spain)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^j UNIVERSITY OF EDINBURGH   (United Kingdom)

^k UNIVERSITY OF HEIDELBERG   (Germany)

more..

Author keywords

Intracranial hemorrhages; Magnetic resonance imaging; Stroke; Subarachnoid hemorrhage; Tissue type plasminogen activator

Indexed keywords

BRAIN HEMATOMA; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DISEASE CLASSIFICATION; HEIDELBERG BLEEDING CLASSIFICATION; HUMAN; INCIDENCE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REPERFUSION THERAPY; THERAPY; TOTAL QUALITY MANAGEMENT; ADVERSE EFFECTS; CLASSIFICATION; COMPLICATION; FIBRINOLYTIC THERAPY; HEMATOMA; INTRACRANIAL HEMORRHAGES; STROKE;

BRAIN ISCHEMIA; HEMATOMA; HUMANS; INTRACRANIAL HEMORRHAGES; MAGNETIC RESONANCE IMAGING; STROKE; THROMBOLYTIC THERAPY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84942886716     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.115.010049     Document Type: Note

References (33)

1. Pessin MS, Del Zoppo GJ, Estol CJ. Thrombolytic agents in the treatment of stroke. Clin Neuropharmacol. 1990;13:271-289.
2. Pessin MS, Teal PA, Caplan LR. Hemorrhagic infarction: guilt by association? AJNR Am J Neuroradiol. 1991;12:1123-1126.
3. von Kummer R, Hacke W. Safety and effcacy of intravenous tissue plas-minogen activator and heparin in acute middle cerebral artery stroke. Stroke. 1992;23:646-652.
4. del Zoppo GJ, Poeck K, Pessin MS, Wolpert SM, Furlan AJ, Ferbert A, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol. 1992;32:78-86. doi: 10.1002/ana.410320113.
5. Wolpert SM, Bruckmann H, Greenlee R, Wechsler L, Pessin MS, del Zoppo GJ. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The rt-PA Acute Stroke Study Group. AJNR Am J Neuroradiol. 1993;14:3-13.
6. Levy DE, Brott TG, Haley EC Jr, Marler JR, Sheppard GL, Barsan W, et al. Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke. Stroke. 1994;25:291-297.
7. del Zoppo GJ, von Kummer R, Hamann GF. Ischaemic damage of brain microvessels: inherent risks for thrombolytic treatment in stroke. J Neurol Neurosurg Psychiatry. 1998;65:1-9.
8. Henning EC, Latour LL, Hallenbeck JM, Warach S. Reperfusion-associated hemorrhagic transformation in SHR rats: evidence of symptomatic parenchymal hematoma. Stroke. 2008;39:3405-3410. doi: 10.1161/STROKEAHA.108.520304.
9. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017-1025.
10. Fiorelli M, Bastianello S, von Kummer R, del Zoppo GJ, Larrue V, Lesaffre E, et al. Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. Stroke. 1999;30:2280-2284.
11. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. New Engl J Med. 1995;333:1581-1587. doi: 10.1056/NEJM199512143332401
12. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352:1245-1251.
13. Berger C, Fiorelli M, Steiner T, Schäbitz WR, Bozzao L, Bluhmki E, et al. Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic? Stroke. 2001;32:1330-1335.
14. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, et al; SITS-MOST Investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369:275-282. doi: 10.1016/S0140-6736(07)60149-4.
15. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329. doi: 10.1056/NEJMoa0804656.
16. Strbian D, Sairanen T, Meretoja A, Pitkäniemi J, Putaala J, Salonen O, et al; Helsinki Stroke Thrombolysis Registry Group. Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis. Neurology. 2011;77:341-348. doi: 10.1212/WNL.0b013e3182267b8c.
17. Saver JL. Hemorrhage after thrombolytic therapy for stroke: the clinically relevant number needed to harm. Stroke. 2007;38:2279-2283. doi: 10.1161/STROKEAHA.107.487009.
18. Rao NM, Levine SR, Gornbein JA, Saver JL. Defning clinically relevant cerebral hemorrhage after thrombolytic therapy for stroke: analysis of the National Institute of Neurological Disorders and Stroke tissue-type plasminogen activator trials. Stroke. 2014;45:2728-2733. doi: 10.1161/STROKEAHA.114.005135.
19. Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al; Stroke Thrombolysis Trialists' Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014;384:1929-1935. doi: 10.1016/S0140-6736(14)60584-5.
20. Whiteley WN, Thompson D, Murray G, Cohen G, Lindley RI, Wardlaw J, et al; IST-3 Collaborative Group. Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intra-cranial hemorrhage or poor functional outcome: an analysis of the third international stroke trial. Stroke. 2014;45:1000-1006. doi: 10.1161/STROKEAHA.113.004362.
21. Smith WS, Sung G, Starkman S, Saver JL, Kidwell CS, Gobin YP, et al; MERCI Trial Investigators. Safety and effcacy of mechanical embo-lectomy in acute ischemic stroke: results of the MERCI trial. Stroke. 2005;36:1432-1438. doi: 10.1161/01.STR.0000171066.25248.1d.
22. Shi ZS, Liebeskind DS, Loh Y, Saver JL, Starkman S, Vespa PM, et al; UCLA Endovascular Stroke Therapy Investigators. Predictors of sub-arachnoid hemorrhage in acute ischemic stroke with endovascular therapy. Stroke. 2010;41:2775-2781. doi: 10.1161/STROKEAHA.110.587063.
23. Saver JL, Jahan R, Levy EI, Jovin TG, Baxter B, Nogueira R, et al; SWIFT Trialists. SOLITAIRE™ with the intention for thrombectomy (SWIFT) trial: design of a randomized, controlled, multicenter study comparing the SOLITAIRE™ Flow Restoration device and the MERCI Retriever in acute ischaemic stroke. Int J Stroke. 2014;9:658-668. doi: 10.1111/j.1747-4949.2012.00856.x.
24. Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al; MR CLEAN Investigators. A randomized trial of intraarte-rial treatment for acute ischemic stroke. N Engl J Med. 2015;372:11-20. doi: 10.1056/NEJMoa1411587.
25. Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI, Pereira VM, et al; SWIFT PRIME Investigators. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med. 2015;372:2285-2295. doi: 10.1056/NEJMoa1415061.
26. Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, et al; REVASCAT Trial Investigators. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. 2015;372:2296-2306. doi: 10.1056/NEJMoa1503780.
27. Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al; ESCAPE Trial Investigators. Randomized assessment of rapid endo-vascular treatment of ischemic stroke. N Engl J Med. 2015;372:1019-1030. doi: 10.1056/NEJMoa1414905.
28. Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, et al; EXTEND-IA Investigators. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015;372:1009-1018. doi: 10.1056/NEJMoa1414792.
29. von Kummer R, Steinhausen T, Papaspyrou H, Karschuk C, Essig M, Egelhof T, et al. Hemorrhagic transformation and contrast enhancement of ischemic brain infarction studied by serial MRI. Stroke. 1993;24:185-185
30. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-pa therapy for ischemic stroke. Stroke. 1997;28:2109-2118. doi: 10.1161/01. STR.28.11.2109
31. Lyden PD, Lu M, Levine SR, Brott TG, Broderick J; NINDS rtPA Stroke Study Group. A modifed National Institutes of Health Stroke Scale for use in stroke clinical trials: preliminary reliability and validity. Stroke. 2001;32:1310-1317.
32. Mazya MV, Ahmed N, Ford GA, Hobohm C, Mikulik R, Nunes AP, et al. Remote or extraischemic intracerebral hemorrhage-an uncommon complication of stroke thrombolysis: results from the safe implementation of treatments in stroke-international stroke thrombolysis register. Stroke. 2014;45:1657-1663. doi: 10.1161/STROKEAHA.114.004923.
33. Tao H, Ramadas G, Carrozzella J, Khatri P, Broderick J, Spilker J, et al; IMS Investigators. Parenchymal hematoma and total lesion volume in combined IV/IA revascularization stroke therapy. J Neurointerv Surg. 2012;4:256-260. doi: 10.1136/neurintsurg-2011-010062.